Review Papers Claim by Claim

Visual paper analysis — "mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival" (Feng & Wu, 2017)

Visualize first, explain second — focused, evidence-weighted critique with clear limitations and next-step experiments. All claims below are inline‑cited to primary literature.

Fig A — Experimental breadth (in vitro scope)

Fig B — Core mechanistic claim (mTORC1 → HIF1a → PFKFB3 → glycolysis → survival)

Concise evidence map (what they measured)

• Genetic activation of mTOR via TSC2 knockdown increases PFKFB3 mRNA and protein in THP1 and OCI‑AML3 cells (WB, qRT‑PCR) Feng & Wu 2017 evidence
• PFKFB3 silencing reduces glucose consumption and cell viability, and activates apoptosis (cleaved caspase‑3, caspase‑9, p‑Bad) in mTOR‑activated cells PFKFB3 KD functional readouts
• mTORC1 dependence: rapamycin treatment or Raptor knockdown reduces PFKFB3; Rictor KD (mTORC2) does not — consistent with transcriptional control via HIF1a mTORC1 → HIF1a evidence
• Therapeutic hint: PFKFB3 inhibitor PFK15 synergizes with rapamycin to reduce viability in TSC2 KD AML cells (dose matrices shown qualitatively in figures) PFK15 + rapamycin combo

Context & external support

PFKFB3 as an oncogenic glycolytic regulator is well-documented across cancer types and endothelial biology; prior high-impact work links PFKFB3 to angiogenesis and proliferation, supporting the biological plausibility of Feng & Wu's AML result PFKFB3 angiogenesis & proliferation

Reviews consolidating PFKFB3 as a therapeutic target emphasize preclinical promise but limited clinical translation and potential context-dependent effects PFKFB3 therapeutic review

Fig C — Direction and qualitative strength of main effects reported

Critical appraisal — strengths

• Clear isoform specificity: PFKFB3 (not PFKFB1/2/4) responds to TSC2 KD — reduces risk of over-generalization to the whole family PFKFB isoform specificity
• Mechanistic linkage to mTORC1 and HIF1a is plausible and experimentally addressed (rapamycin, Raptor KD, HIF1a KD), not merely correlative.
• Therapeutic synergy experiments (rapamycin + PFK15) give translationally useful hypothesis for combination therapy in mTOR‑hyperactive AML contexts.

Critical appraisal — limitations & blindspots

• No in vivo data or primary patient samples — limits clinical generalizability beyond cell lines (THP1 and OCI‑AML3 are informative but not exhaustive). This is the single largest blindspot for therapeutic claims No in vivo/patient data
• Limited quantification/reporting details: figures and legends summarize effects but numerical replicates, exact n per experiment and statistical power are not always explicit in the TEI text; reproducibility would benefit from fully deposited raw data and representative replicate blots.
• PFK15 specificity and off-targets: small-molecule inhibitors can have off-target actions; independent chemical probes or genetic rescue (PFKFB3 re-expression resistant to siRNA) would strengthen causality (not shown).
• AML heterogeneity: AML subtypes and primary blasts vary in metabolism; two cell lines cannot capture this variability — risk of over-generalizing to all AML patients.
• Mechanistic depth: while HIF1a transcriptional regulation is shown, the paper does not examine chromatin occupancy (ChIP) at the PFKFB3 promoter, nor mTOR-dependent translation control of PFKFB3 mRNA, leaving some mechanistic unknowns.

High‑value follow-up experiments (priority-ranked)

1. In vivo validation: test TSC2 KD and PFKFB3 inhibition (PFK15 or genetic) in AML xenograft models and patient-derived xenografts (PDX) to measure tumor burden, survival, and systemic toxicity.
2. Patient relevance: measure PFKFB3 protein and mRNA in primary AML blasts (panel of subtypes) and correlate with phospho‑S6 (mTOR activity) to test whether mTOR‑PFKFB3 axis operates in patient material.
3. Rescue experiments: re-expression of siRNA‑resistant PFKFB3 to rescue glycolysis and proliferation after KD to confirm on‑target effects; use an orthogonal PFKFB3 inhibitor and CRISPR KO/knock-in to address small‑molecule off‑targets.
4. ChIP and promoter analysis: test HIF1a binding to PFKFB3 promoter under TSC2 KD and rapamycin treatment to confirm direct transcriptional control.
5. Metabolic flux: Seahorse ECAR/OCR and F2,6BP measurements and stable isotope tracing (13C‑glucose) to quantify glycolytic flux changes with PFKFB3 manipulation.

(Launches an iterative bioinformatics/analysis agent to run requested in silico follow-ups: expression meta‑analysis, drug synergy modelling, or re-analysis of raw data.)

Citations used in this analysis

Primary paper and contextual PFKFB3 literature (inline details available above):

• Feng & Wu 2017 (primary paper)
• PFKFB3 angiogenesis & proliferation
• PFKFB3 therapeutic review